Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

05 October 2014 : Original article  

Independent Factors for Prediction of Poor Outcomes in Patients with Febrile Neutropenia

Müge GünalpABCDEF, Merve KoyunoğluABD, Serdar GürlerABD, Ayça KocaABDE, İlker YeşilkayaB, Emre ÖnerB, Meltem AkkaşADEF, Nalan Metin AksuADE, Arda DemirkanDE, Onur PolatDE, Atilla Halil ElhanC

DOI: 10.12659/MSM.892269

Med Sci Monit 2014; 20:1826-1832

Abstract

BACKGROUND: Febrile neutropenia (FN) is a life-threatening condition that requires urgent management in the emergency department (ED). Recent progress in the treatment of neutropenic fever has underscored the importance of risk stratification. In this study, we aimed to determine independent factors for prediction of poor outcomes in patients with FN.

MATERIAL AND METHODS: We retrospectively evaluated 200 chemotherapy-induced febrile neutropenic patients who visited the ED. Upon arrival at the ED, clinical data, including sex, age, vital signs, underlying systemic diseases, laboratory test results, estimated GFR, blood cultures, CRP, radiologic examinations, and Multinational Association of Supportive Care in Cancer (MASCC) score of all febrile neutropenic patients were obtained. Outcomes were categorized as “poor” if serious complications during hospitalization, including death, occurred.

RESULTS: The platelet count <50 000 cells/mm3 (OR 3.90, 95% CI 1.62–9.43), pulmonary infiltration (OR 3.45, 95% CI 1.48–8.07), hypoproteinemia <6 g/dl (OR 3.30, 95% CI 1.27–8.56), respiratory rate >24/min (OR 8.75, 95% CI 2.18–35.13), and MASCC score <21 (OR 9.20, 95% CI 3.98–21.26) were determined as independent risk factors for the prediction of death. The platelet count <50 000 cells/mm3 (OR 3.93, 95% CI 1.42–10.92), serum CRP >50 mg/dl (OR 3.80, 95% CI 1.68–8.61), hypoproteinemia (OR 7.81, 95% CI 3.43-17.78), eGFR ≤90 ML/min/1.73 m2 (OR 3.06, 95% CI 1.13–8.26), and MASCC score <21 (OR 3.45, 95% CI 1.53–7.79) were determined as independent risk factors for the prediction of poor clinical outcomes of FN patients. Platelet count, protein level, respiratory rate, pulmonary infiltration, CRP, MASCC score, and eGFR were shown to have a significant association with outcome.

CONCLUSIONS: The results of our study may help emergency medicine physicians to prevent serious complications with proper use of simple independent risk factors besides MASCC score.

Keywords: Antineoplastic Agents - adverse effects, Febrile Neutropenia - physiopathology, Outcome Assessment (Health Care)

Add Comment 0 Comments

Editorial

01 January 2025 : Editorial  

Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?

Dinah V. Parums

DOI: 10.12659/MSM.947707

Med Sci Monit 2025; 31:e947707

0:00

In Press

Clinical Research  

Impact of Periodontal Treatment on Early Rheumatoid Arthritis and the Role of Porphyromonas gingivalis Anti...

Med Sci Monit In Press; DOI: 10.12659/MSM.947146  

Clinical Research  

C-Reactive Protein, Uric Acid, and Coronary Artery Ectasia in Patients with Coronary Artery Disease

Med Sci Monit In Press; DOI: 10.12659/MSM.947158  

Clinical Research  

Effects of Remote Exercise on Physical Function in Pre-Frail Older Adults: A Randomized Controlled Trial

Med Sci Monit In Press; DOI: 10.12659/MSM.947105  

Database Analysis  

Development and Validation of a Competitive Risk Model in Elderly Patients with Transitional Cell Bladder C...

Med Sci Monit In Press; DOI: 10.12659/MSM.946332  

Most Viewed Current Articles

17 Jan 2024 : Review article   6,964,204

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research   700,526

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Mar 2024 : Editorial   24,009

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...

DOI :10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

28 Jan 2024 : Review article   18,806

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

DOI :10.12659/MSM.943912

Med Sci Monit 2024; 30:e943912

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750